Cardium Therapeutics, Inc. (CXM) Swings to Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CXM Hot Sheet
Price: $6.69 --0%
Revenue Growth %: -1.3%
Financial Fact:
Loss per common share - basic and diluted: -0.14
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -1.3%
Financial Fact:
Loss per common share - basic and diluted: -0.14
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Cardium Therapeutics, Inc. (AMEX: CXM) reported Q4 EPS of ($0.02), versus $0.01 reported last year.
For earnings history and earnings-related data on Cardium Therapeutics, Inc. (CXM) click here.
For earnings history and earnings-related data on Cardium Therapeutics, Inc. (CXM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- UBS Reiterates Buy Rating on Expeditors Int'l (EXPD)
- AMTD Digital reports $1.2B in total assets, $42.4M profit
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
